Drug Profile
THR 149
Alternative Names: THR-149Latest Information Update: 22 Nov 2023
Price :
$50
*
At a glance
- Originator Bicycle Therapeutics
- Developer Bicycle Therapeutics; Oxurion
- Class Bicyclic peptides; Eye disorder therapies; Peptides; Small molecules
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic macular oedema
Most Recent Events
- 20 Nov 2023 Efficacy and adverse events data from phase II KALAHARI trial in Diabetic macular edema released by Oxurion
- 28 Sep 2023 Oxurion completes the phase II KALAHARI trial in Diabetic macular oedema (In adults, In the elderly, Treatment-experienced) in USA, Italy, Czech Republic, France, Germany, Slovakia, Spain, UK (Intravitreous) (EudraCT2019-001506-17) (NCT04527107)
- 13 Jun 2023 Oxurion completes enrolment in its Phase-II clinical trials in Diabetic macular oedema (In adults, In the elderly, Treatment-experienced) in the US, Italy, Czechia, France, Germany, Slovakia, Spain, UK (Intravitreous) (EudraCT2019-001506-17) (NCT04527107)